4D pharma Announces Passing of Chief Financial Officer John Beck
4D pharma plc (NASDAQ: LBPS) announces the passing of its Chief Financial Officer, John Beck, who had over 30 years of experience in the financial and biopharmaceutical industries. CEO Duncan Peyton expressed deep sorrow over Beck’s loss, highlighting his invaluable contributions to the company and the vision he had for its future. Despite this tragic event, 4D pharma's management team and Board of Directors will continue to lead the company, with succession planning in progress. 4D pharma specializes in developing Live Biotherapeutics, a new class of drugs derived from the microbiome.
- 4D pharma continues with a strong management team and Board of Directors despite the loss of CFO John Beck.
- The company has a diverse pipeline with five clinical programs, including promising studies in oncology and asthma.
- The loss of John Beck could create uncertainty within the company as it undergoes succession planning.
4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announces with great sadness that John Beck, Chief Financial Officer of 4D pharma, has passed away.
“We are deeply saddened by John’s passing. The entire 4D pharma community mourns this loss and, on behalf of our Board of Directors and employees, we extend our sincerest condolences to his family,” said Duncan Peyton, Chief Executive Officer of 4D pharma. “John’s 30 years of experience in the financial and biopharmaceutical industries were invaluable to us in his role as Chief Financial Officer, and his vision for the future of 4D pharma was already well on its way to being realized. We grieve this loss and will carry his legacy forward in this next chapter of 4D pharma continued growth and progress.”
4D pharma will continue to be actively led by its current management team and Board of Directors and succession planning is underway.
About 4D pharma
4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005352/en/
FAQ
What happened to the CFO of 4D pharma (LBPS)?
What is 4D pharma's focus area in pharmaceuticals?
How many clinical programs does 4D pharma currently have?
What is the significance of Live Biotherapeutics?
